Business
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know
April 8, 2026
The Motley Fool
Scroll
Focused on innovative dermatology treatments, this biopharma firm reported a notable insider sale amid a strong year for its shares.
The Motley Fool
Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.
United States of America
Bias: lean left